Gaining insights into the consequences of target-mediated drug disposition of monoclonal antibodies using quasi-steady-state approximations

Journal of Pharmacokinetics and Pharmacodynamics

Volumn 36, Issue 5, 2009, Pages 407-420

  Grimm, Hans Peter ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Mathematical modeling; Michaelis Menten elimination; Monoclonal antibodies; Non linear pharmacokinetics; Target mediated drug disposition

Indexed keywords

MONOCLONAL ANTIBODY;

ANTIBODY SPECIFICITY; ARTICLE; COMPARTMENT MODEL; CONTROLLED STUDY; DRUG DISPOSITION; NONLINEAR SYSTEM; PHARMACODYNAMICS; PRIORITY JOURNAL; STEADY STATE; TURNOVER TIME;

ALGORITHMS; ANTIBODIES, MONOCLONAL; COMPUTER SIMULATION; DRUG DELIVERY SYSTEMS; HUMANS; NONLINEAR DYNAMICS; PERMEABILITY; RECEPTORS, DRUG; TISSUE DISTRIBUTION;

EID: 70350570662     PISSN: 1567567X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10928-009-9129-5     Document Type: Article

References (19)

1. D Mould K Sweeney 2007 The pharmacokinetics and pharmacodynamics of monoclonal antibodies mechanistic modeling applied to drug development Curr Opin Drug Discov Devel 10 1 84 96 1:CAS:528:DC%2BD2sXpsVGksw%3D%3D 17265746
2. DE Mager WJ Jusko 2001 General pharmacokinetic model for drugs exhibiting target-mediated drug disposition J Pharmacokinet Pharmacodyn 28 6 507 532 10.1023/A:1014414520282 1:CAS:528:DC%2BD38XjsFSrtro%3D 11999290 (Pubitemid 34289541)
3. GML Meno-Tetang PJ Lowe 2005 On the prediction of the human response: a recycled mechanistic pharmacokinetic/pharmacodynamic approach Basic Clin Pharmacol Toxicol 96 3 182 192 10.1111/j.1742-7843.2005.pto960307.x 1:CAS:528:DC%2BD2MXisFSmu7s%3D 15733213 (Pubitemid 40387994)
4. CM Ng, et al. 2005 Pharmacokinetic-pharmacodynamic-efficacy analysis of efalizumab in patients with moderate to severe psoriasis Pharm Res 22 7 1088 1100 10.1007/s11095-005-5642-4 1:CAS:528:DC%2BD2MXmt1yntbw%3D 16028009 (Pubitemid 41127066)
5. CM Ng, et al. 2006 Pharmacokinetics/pharmacodynamics of nondepleting anti-CD4 monoclonal antibody (TRX1) in healthy human volunteers Pharm Res 23 1 95 103 10.1007/s11095-005-8814-3 1:CAS:528:DC%2BD28Xht1Cltr8%3D 16308668 (Pubitemid 43214665)
6. JM Kovarik, et al. 2001 A population pharmacokinetic screen to identify demographic-clinical covariates of basiliximab in liver transplantation Clin Pharmacol Ther 69 4 201 209 10.1067/mcp.2001.114887 1:CAS:528: DC%2BD3MXjvVelsbw%3D 11309548 (Pubitemid 32382502)
7. J-F Lu, et al. 2008 Clinical pharmacokinetics of bevacizumab in patients with solid tumors Cancer Chemother Pharmacol 62 5 779 786 10.1007/s00280-007- 0664-8 1:CAS:528:DC%2BD1cXht1CjtL3E 18205003
8. DR Mould, et al. 2007 Population pharmacokinetics-pharmacodynamics of alemtuzumab (Campath®) in patients with chronic lymphocytic leukaemia and its link to treatment response Br J Clin Pharmacol 64 3 278 291 10.1111/j.1365-2125.2007.02914.x 10.1111/j.1365-2125.2007.02914.x 1:CAS:528:DC%2BD2sXhtFKis7%2FL 17506867 (Pubitemid 47283867)
9. CM Ng, et al. 2005 Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial J Clin Pharmacol 45 7 792 801 10.1177/0091270005277075 10.1177/0091270005277075 1:CAS:528:DC%2BD2MXmsFymtLY%3D 15951469 (Pubitemid 40875331)
10. D Ternant, et al. 2008 Infliximab pharmacokinetics in inflammatory bowel disease patients Ther Drug Monit 30 4 523 529 1:CAS:528:DC%2BD1cXpsVCiu7c%3D 18641542
11. Z Xu, et al. 2008 Population pharmacokinetics of infliximab in patients with ankylosing spondylitis J Clin Pharmacol 48 6 681 695 10.1177/ 0091270008316886 10.1177/0091270008316886 1:CAS:528:DC%2BD1cXns1Kitrk%3D 18401017 (Pubitemid 351713154)
12. Nolting A, Fox FE, Kovar A (2006) Clinical drug development of cetuximab, a monoclonal antibody. In: Meibohm B (ed) Pharmacokinetics and pharmacodynamics of biotech drugs: principles and case studies in drug development. WILEY-VCH, Weinheim, pp 353-370
13. FDA (2006) Clinical pharmacology biopharmaceutics review(s): vectibix panitumumab injectable. FDA, Center for Drug Evaluation and Research, Rockville
14. DE Mager 2006 Target-mediated drug disposition and dynamics Biochem Pharmacol 72 1 1 10 10.1016/j.bcp.2005.12.041 1:CAS:528:DC%2BD28Xltl2gt78%3D 16469301 (Pubitemid 43795346)
15. D Mager W Krzyzanski 2005 Quasi-equilibrium pharmacokinetic model for drugs exhibiting target-mediated drug disposition Pharm Res 22 10 1589 1596 10.1007/s11095-005-6650-0 1:CAS:528:DC%2BD2MXhtVent7vO 16180117 (Pubitemid 41355898)
16. L Gibiansky, et al. 2008 Approximations of the target-mediated drug disposition model and identifiability of model parameters J Pharmacokinet Pharmacodyn 35 573 591 10.1007/s10928-008-9102-8 1:CAS:528:DC%2BD1cXhsFSmtLrK 19005743
17. Holmes MH (1995) Introduction to perturbation methods. In: Marsden JE, et al (eds) Texts in applied mathematics, vol 20, 1 edn. Springer-Verlag, New York p 337
18. A Marathe W Krzyzanski DE Mager 2009 Numerical validation and properties of a rapid binding approximation of a target-mediated drug disposition pharmacokinetic model J Pharmacokinet Pharmacodyn 36 199 219 10.1007/s10928-009-9118-8 1:CAS:528:DC%2BD1MXnvVOgs74%3D 19434483
19. M Orditura, et al. 2009 Correlation between efficacy and skin rash occurrence following treatment with the epidermal growth factor receptor inhibitor cetuximab: a single institution retrospective analysis Oncol Rep 21 4 1023 1028 10.3892/or-00000319 1:CAS:528:DC%2BD1MXksVSrt7g%3D 19288004